Shares of Panacea Biotec Ltd jumped nearly 15 percent on Tuesday after the company announced the launch of DENSTAR, a global initiative aimed at advancing the licensing and access of its dengue vaccine candidate DengiAll®.
The stock rose as much as 14.5 percent to Rs. 633.35, compared with its previous close of Rs. 553.25. Panacea Biotec has a market capitalization of Rs. 3,791.42 crore.
Four-year project backed by EU-funded programme
The DENSTAR project is a four-year initiative focused on expanding the availability of DengiAll® and supporting its broader global use.
The project is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), which is supported by the European Union.
It is being coordinated by the Sclavo Vaccines Association, a non-profit organization based in Siena, Italy.
Global consortium spans nine countries
The initiative brings together 10 partners from nine countries across:
- Europe
- Africa
- India
- South Korea
- United States
The consortium includes:
- Universities
- Research institutions
- Non-profit organizations
- A biotechnology company
Panacea Biotec, the developer of DengiAll®, is one of the partners in the project.
Clinical studies planned in Africa
Under the DENSTAR programme, the consortium will conduct Phase 1/3 clinical studies involving healthy adults and children in Africa.
The project will also use Controlled Human Infection Models (CHIMs) to evaluate protection against Dengue Virus Serotype 4 (DENV-4).
These studies are aimed at strengthening evidence required for regulatory approval and wider use.
Features of DengiAll®
According to the company, DengiAll® is designed as:
- A single-dose vaccine
- A tetravalent dengue vaccine
- A cost-efficient product
- A scalable immunization solution
The vaccine does not require prior serological testing, which could simplify deployment across large populations.
Focus on Africa and low-income countries
The initiative seeks to improve access to dengue vaccines in sub-Saharan Africa, where outbreaks have been increasing.
There is currently no specific antiviral treatment for dengue, and existing preventive measures provide only partial protection.
The project aims to support regulatory approval and facilitate wider access to DengiAll® in Africa and other regions.
Financial performance
For the quarter ended March 2026, Panacea Biotec reported revenue of Rs. 166.75 crore, up from Rs. 132.53 crore in the corresponding period of the previous year.
Net loss narrowed to Rs. 1 crore from Rs. 1.99 crore a year earlier.
About the company
Panacea Biotec is engaged in the research, development and manufacturing of:
- Vaccines
- Complex generic pharmaceuticals
- Biosimilars
- Nutraceutical products
The company has supplied more than 10 billion doses of oral polio vaccines and has several vaccine candidates under development, including pneumococcal and dengue vaccines.
Key highlights
| Particulars | Details |
|---|---|
| Stock gain | 14.5% |
| Market capitalization | Rs. 3,791.42 crore |
| Project | DENSTAR |
| Vaccine candidate | DengiAll® |
| Project duration | Four years |
| Partners | 10 organizations |
| Countries involved | 9 |
| Funding support | EU-backed GH EDCTP3 JU |
TL;DR:
Panacea Biotec shares surged nearly 15 percent after the launch of the EU-backed DENSTAR project, a four-year initiative aimed at advancing clinical development and global access for its dengue vaccine candidate DengiAll®.
AI summary:
- Panacea Biotec rose nearly 15% on Tuesday.
- The company launched the four-year DENSTAR project.
- The initiative is backed by the EU-funded GH EDCTP3 programme.
- Phase 1/3 studies will be conducted in Africa.
- DengiAll® is a single-dose tetravalent dengue vaccine candidate.
